Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
- Details
ClinicalTrials.gov ID:
NCT03310957
Diagnosis Type:
NA
USOR Number:
- Address
4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2068